Amphastar Pharmaceuticals (AMPH) Enterprise Value (2013 - 2026)

Amphastar Pharmaceuticals' Enterprise Value history runs 14 years deep, the most recent figure standing at -$171.1 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 6.47% year-over-year to -$171.1 million in Q1 2026; TTM through Mar 2026 was -$171.1 million, a 6.47% increase from a year earlier, with the FY2025 full-year figure at -$170.4 million, down 10.79% from the prior year.
• Enterprise Value held at -$171.1 million in Q1 2026 per AMPH's latest filing, from -$170.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$144.5 million in Q4 2023 and bottomed at -$271.0 million in Q3 2023.
• The 5-year median for Enterprise Value is -$172.8 million (2022), against an average of -$181.3 million.
• Across the five-year window, Enterprise Value plunged 206.25% in 2022 and climbed 29.04% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$156.3 million in 2022, then gained by 7.57% to -$144.5 million in 2023, then slipped by 6.45% to -$153.8 million in 2024, then slipped by 10.79% to -$170.4 million in 2025, then decreased by 0.43% to -$171.1 million in 2026.
• Per Business Quant, the three latest AMPH Enterprise Value figures stand at -$171.1 million (Q1 2026), -$170.4 million (Q4 2025), and -$216.5 million (Q3 2025).